shares outstanding
(thousands) -
diluted 1,090,228 1,086,412 1,090,095 1,086,449
N/M - not meaningful
Eli Lilly and Company
Operating Results (Unaudited) - PRO FORMA ADJUSTED
(Dollars in millions, except per share data)
Three Months Nine Months
Ended Sept. 30 Ended Sept. 30
2007(a)(b) 2006(b) % Chg. 2007(a)(b) 2006(b) %Chg.
---------------------------------------------------------
Net sales $4,586.8 $4,054.7 13% $13,516.6 $11,986.3 13%
Cost of sales 1,054.6 906.2 16% 2,991.9 2,663.3 12%
Research and
development 844.5 788.8 7% 2,545.1 2,370.1 7%
Marketing and
administrative 1,477.8 1,302.3 13% 4,375.2 3,886.1 13%
------- ------- ------- -------
Operating income 1,209.9 1,057.4 14% 3,604.4 3,066.8 18%
Net interest income
(expense) (6.2) (34.2) (23.4) (108.9)
Joint-venture
income - - - -
Net other income 56.0 29.4 91.8 73.4
---- ---- ---- ----
Other income
(deductions) 49.8 (4.8) 68.4 (35.5)
Income before
income taxes 1,259.7 1,052.6 20% 3,672.8 3,031.3 21%
Income taxes 263.3 220.6 19% 795.8 630.8 26%
----- ----- ----- -----
Net income $996.4 $832.0 20% $2,877.0 $2,400.5 20%
------ ------
'/>"/>
| SOURCE Eli Lilly and Company Copyright©2007 PR Newswire. All rights reserved |